Lucid Diagnostics Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Lucid Diagnostics's estimated annual revenue is currently $28.4M per year.(i)
  • Lucid Diagnostics's estimated revenue per employee is $251,000

Employee Data

  • Lucid Diagnostics has 113 Employees.(i)
  • Lucid Diagnostics grew their employee count by 55% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.3M29-9%N/AN/A
#2
$36.4M1452%N/AN/A
#3
$6.5M268%N/AN/A
#4
$8.5M346%N/AN/A
#5
$7.5M17-15%$6.5MN/A
#6
$5.5M2222%N/AN/A
#7
$11.5M4618%N/AN/A
#8
$20.6M8211%N/AN/A
#9
$26.9M107-8%N/AN/A
#10
$4M160%N/AN/A
Add Company

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

keywords:N/A

N/A

Total Funding

113

Number of Employees

$28.4M

Revenue (est)

55%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lucid Diagnostics News

2022-04-17 - Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus ...

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with...

2022-04-17 - Lucid Diagnostics to Hold a Business Update Conference Call ...

Lucid Diagnostics Inc is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on...

2022-03-30 - Lucid Diagnostics Provides Updates on Newly Published ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M11311%N/A
#2
$28.4M113-18%N/A
#3
$30.5M1134%N/A
#4
$16.4M1139%N/A
#5
$28.3M11327%N/A